Overview of the Offering#
Travere Therapeutics, Inc., based in San Diego, has announced the pricing of an underwritten offering of $475 million in convertible senior notes due in 2032. This amount is an increase from the previously planned $400 million. The company has also given underwriters a 30-day option to purchase an additional $50 million in notes to cover any excess demand. The sale is expected to close on May 11, 2026, pending standard closing conditions.
Details of the Convertible Notes#
The convertible notes will have a low annual interest rate of 0.50%, which will be paid out in cash every six months. They are set to mature on May 15, 2032. The initial conversion rate allows investors to convert each $1,000 of notes into approximately 15.41 shares of Travere stock, translating to a conversion price of about $64.90 per share. This price is 45% higher than the current stock price of $44.76, although the stock has seen a significant increase of 121% over the past year.
Use of Proceeds#
Travere expects to net around $460 million from this offering, or about $508.5 million if the underwriters fully exercise their option. The company plans to use approximately $350.9 million of these proceeds to buy back some of its existing 2.25% senior convertible notes due in 2029. The remaining funds will be allocated for various corporate purposes, including expenses related to commercialization, clinical trials, and general administrative costs.
Financial Position and Future Outlook#
Travere's financial health appears to be improving, with liquid assets surpassing short-term liabilities and a current ratio of 3.13. Although the company reported a loss of $0.51 per share over the past year, analysts predict earnings of $1.92 per share for 2026, indicating a potential return to profitability. Additionally, the company has reported mixed financial results for the first quarter of 2026, with earnings per share falling short of expectations.